Johnson & Johnson‘s (NYSE:JNJ) Janssen revealed data today from two Phase III trials of its investigational esketamine nasal spray in patients with treatment-resistant depression.
The Titusville, N.J.-based company said that if approved by the FDA, esketamine would represent one of the first new approaches designed to treat refractory major depressive disorder in the last 50 years.
Get the full story at our sister site, Drug Delivery Business News.
The post J&J’s Janssen touts Ph3 data for antidepressant nasal spray appeared first on MassDevice.